Skip to main content

CASE REPORT article

Front. Immunol.

Sec. Primary Immunodeficiencies

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1572791

This article is part of the Research Topic Community Series in Primary Immunodeficiencies Worldwide: Volume III View all articles

Case Report: CD40LG Arg203Ile Variant Underlies Atypical Phenotype of X-Linked Hyper IgM Syndrome

Provisionally accepted
  • 1 Kagoshima University, Kagoshima, Japan
  • 2 Tokyo Medical and Dental University, Tokyo, Japan
  • 3 Tokyo University of Pharmacy and Life Sciences, Hachioji, Tōkyō, Japan
  • 4 Kagoshima University Hospital, Kagoshima, Kagoshima, Japan
  • 5 Seattle Children's Research Institute, Seattle, Washington, United States

The final, formatted version of the article will be published soon.

    Hyper IgM syndrome (HIGM) is a rare immunodeficiency caused by impaired immunoglobulin class switching, leading to recurrent infections. The present report describes the case of an 18-year-old man initially diagnosed with common variable immunodeficiency at 3 years of age. Genetic analysis revealed a hemizygous CD40LG missense variant (p.Arg203Ile) associated with X-linked HIGM (XHIGM). Structural and flow cytometric analyses indicated normal CD40 ligand (CD40L) expression on activated CD4 + T-cells but impaired CD40 binding, indicating disrupted immune signaling. Notably, the patient experienced neither bacterial infections requiring hospitalization nor opportunistic infections during 15 years of immunoglobulin replacement therapy. These findings indicate that the p.Arg203Ile variant destabilizes CD40L-CD40 interactions without affecting CD40L expression, suggesting a hypomorphic phenotype. This report highlights the importance of combining genetic testing with functional analysis when evaluating atypical XHIGM presentations to predict clinical severity and provide a scientific basis for personalized treatment strategies. Additional studies are required to assess the long-term outcomes and potential curative therapies for similar cases.

    Keywords: Atypical phenotype, CD40 Ligand, Immunoglobulin replacement therapy, structural stability assessment, X-linked hyper IgM syndrome

    Received: 07 Feb 2025; Accepted: 27 Mar 2025.

    Copyright: © 2025 Nishikawa, Tomomasa, Hijikata, Kasabata, Okamoto, Ochs and Kanegane. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Takuro Nishikawa, Kagoshima University, Kagoshima, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more